Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP): Price and Financial Metrics


Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP): $99.76

-0.02 (-0.02%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

HZNP POWR Grades


  • HZNP scores best on the Sentiment dimension, with a Sentiment rank ahead of 60.18% of US stocks.
  • The strongest trend for HZNP is in Momentum, which has been heading down over the past 31 weeks.
  • HZNP ranks lowest in Momentum; there it ranks in the 11th percentile.

HZNP Stock Summary

  • With a year-over-year growth in debt of 89.83%, Horizon Therapeutics Public Ltd Co's debt growth rate surpasses 90.51% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Horizon Therapeutics Public Ltd Co is reporting a growth rate of 441.92%; that's higher than 95.29% of US stocks.
  • As for revenue growth, note that HZNP's revenue has grown 58.98% over the past 12 months; that beats the revenue growth of 90.53% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Horizon Therapeutics Public Ltd Co are NICE, TTWO, CTLT, UMC, and PTC.
  • Visit HZNP's SEC page to see the company's official filings. To visit the company's web site, go to www.horizontherapeutics.com.

HZNP Valuation Summary

  • HZNP's price/sales ratio is 10.4; this is 12.24% lower than that of the median Healthcare stock.
  • Over the past 122 months, HZNP's EV/EBIT ratio has gone up 81.9.
  • HZNP's price/earnings ratio has moved up 85 over the prior 122 months.

Below are key valuation metrics over time for HZNP.

Stock Date P/S P/B P/E EV/EBIT
HZNP 2019-06-19 3.5 3.0 88.6 41.0
HZNP 2017-06-26 2.0 1.6 -9.2 -14.7
HZNP 2016-11-21 3.8 2.5 -281.3 -2216.5
HZNP 2013-12-11 8.0 6.2 -6.2 -7.3
HZNP 2012-12-24 8.8 1.1 -1.0 -0.5
HZNP 2012-06-06 17.5 1.6 -1.0 -0.8

HZNP Growth Metrics

  • Its 2 year price growth rate is now at 208.47%.
  • The 2 year net cashflow from operations growth rate now stands at 54.81%.
  • Its 3 year revenue growth rate is now at 48.96%.
HZNP's revenue has moved up $1,570,579,000 over the prior 67 months.

The table below shows HZNP's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 2,186.926 614.553 280.036
2020-12-31 2,200.429 555.688 389.796
2020-09-30 1,818.66 337.251 792.008
2020-06-30 1,517.699 315.904 517.402
2020-03-31 1,375.567 307.571 592.292
2019-12-31 1,300.029 426.332 573.02

HZNP Price Target

For more insight on analysts targets of HZNP, see our HZNP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $114.18 Average Broker Recommendation 1.29 (Strong Buy)

HZNP Stock Price Chart Interactive Chart >

Price chart for HZNP

HZNP Price/Volume Stats

Current price $99.76 52-week high $104.86
Prev. close $99.78 52-week low $60.82
Day low $97.23 Volume 1,949,600
Day high $100.27 Avg. volume 1,721,850
50-day MA $94.62 Dividend yield N/A
200-day MA $85.22 Market Cap 22.42B

Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP) Company Bio


Horizon Pharma plc engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. The company was founded in 2005 and is based in Dublin, Ireland.

HZNP Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$99.76$118.33 26%

Below please find a table outlining a discounted cash flow forecast for HZNP, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Horizon Therapeutics Public Ltd Co ranked in the 60th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. The most interesting components of our discounted cash flow analysis for Horizon Therapeutics Public Ltd Co ended up being:

  • The company's compound free cash flow growth rate over the past 5.5 years comes in at 0.48%; that's greater than 78.8% of US stocks we're applying DCF forecasting to.
  • The company has produced more trailing twelve month cash flow than 68.35% of its sector Healthcare.
  • Horizon Therapeutics Public Ltd Co's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%23%
1%25%
2%26%
3%27%
4%28%
5%30%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as HZNP, try DVA, AMPH, ESMC, JAZZ, and PRAH.


HZNP Latest News Stream


Event/Time News Detail
Loading, please wait...

HZNP Latest Social Stream


Loading social stream, please wait...

View Full HZNP Social Stream

Latest HZNP News From Around the Web

Below are the latest news stories about Horizon Therapeutics Public Ltd Co that investors may wish to consider to help them evaluate HZNP as an investment opportunity.

10 Promising Stocks to Buy That Are Getting Lots of Analyst Love

Analysts' reports can be an easy way to gauge market sentiment, particularly if you are confused regarding which stocks to buy.

Faizan Farooque on InvestorPlace | July 30, 2021

The Daily Biotech Pulse: Merck''s Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs

Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV ) Alkermes plc (NASDAQ: ALKS ) (reacted to second-quarter results) Arvinas, Inc. (NASDAQ: ARVN ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BioNTech SE (NASDAQ: BNTX ) (reacted to COVID-19 vaccine sales revealed by Pfizer, Inc. in its quarterly results) Cassava Sciences, Inc. (NASDAQ: SAVA ) (saw an acceleration in momentum set in motion by Alzheimer''s data release) Edwards Lifesciences Corporation (NYSE: EW ) Globus Medical, Inc. (NYSE: GMED ) Horizon Therapeutics Public Limited Company (NASDAQ: HZNP ) Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD ) Merit Medical Systems, Inc. (NASDAQ: MMSI ) Repligen Corporation (NASDA...

Benzinga | July 29, 2021

3 Monster Growth Stocks That Can Rip Higher

No matter what strategy an investor follows, the end result in view is always to find the strongest returns. That return on investment is where the profits lie – profits that can be pocketed, or spent, or reinvested to expand the portfolio. Finding them is the trick. For a savvy investor, a good starting point is filtering through the ‘noisy’ market data and finding stocks that feature both strong fundamentals and a solid growth history. Seeking out the stocks that have delivered returns, and ar

Yahoo | July 26, 2021

The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs

Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) Bio-Techne Corporation (NASDAQ: TECH ) BioNTech SE (NASDAQ: BNTX ) (announced a collaboration with Biovac to manufacture COVID-19 shots in South Africa) Bristol-Myers Squibb Company (NYSE: BMY ) Cassava Sciences, Inc. (NASDAQ: SAVA ) Century Therapeutics, Inc. (NASDAQ: IPSC ) Cortexyme, Inc. (NASDAQ: CRTX ) (announced positive data for pipeline asset in periodontal disease) Eli Lilly and Company (NYSE: LLY ) Erasca, Inc. (NASDAQ: ERAS ) (IPOed July 16) Horizon Therapeutics Public Limited Company (NASDAQ: HZNP ) Legend Biotech Corporation (NASDAQ: LEGN ) NeuroMetrix, Inc. (NASDAQ: NURO ) (reacted to its second-quarter results) Novo Nordisk A/...

Benzinga | July 23, 2021

Can You Imagine How Elated Horizon Therapeutics' (NASDAQ:HZNP) Shareholders Feel About Its 463% Share Price Gain?

We think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many...

Yahoo | July 23, 2021

Read More 'HZNP' Stories Here

HZNP Price Returns

1-mo N/A
3-mo 10.99%
6-mo 17.06%
1-year 61.45%
3-year 455.15%
5-year 396.32%
YTD 36.38%
2020 102.07%
2019 85.26%
2018 33.84%
2017 -9.77%
2016 -25.33%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8832 seconds.